NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model
about
Functional Mechanisms of Treg in the Context of HIV Infection and the Janus Face of Immune SuppressionMonoclonal antibodies targeting CD38 in hematological malignancies and beyondEndothelial Progenitor Cells Physiology and Metabolic Plasticity in Brain Angiogenesis and Blood-Brain Barrier ModelingAdenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.Antibody mimicry, receptors and clinical applications.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formationRoles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche.Targeting immunosuppressive adenosine in cancer.Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging.Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity.Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.Daratumumab for the Treatment of Multiple Myeloma.Daratumumab induces CD38 internalization and impairs myeloma cell adhesionCD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceStromal CD38 regulates outgrowth of primary melanoma and generation of spontaneous metastasisPerspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
P2860
Q26744626-8A8CD0E5-0262-40BA-9A0E-7DE3AD40F5F7Q26766718-97FBE4C8-6471-4BCE-AADE-26918143F978Q28072654-D41ABFD8-CFFC-44A0-BEDF-F9BBEFBC60ECQ37468697-601570F9-6F38-4B0F-A7D5-91C2624B9495Q39062940-36687EC7-7511-4AB4-9B41-AE864699517CQ39177792-1B65A53A-81B7-4F7D-BF70-4960E5DF6654Q41345636-02B0D498-353E-48FC-AEF9-24845AC60761Q41959993-1DD1C11B-5386-4B7B-BB57-6AC964985BB5Q46140918-B729002C-1949-4FC9-828E-E907463F39CDQ47660573-F5CF75EC-3AE1-4961-86D0-ABA3C07C3F93Q51767119-BEAB3DD3-544C-4595-8831-521494B4E4A6Q54986388-8222F2EF-07E6-42BB-9BB8-931961CB9F5BQ55025877-C35BA847-3823-421A-8B48-A2973DC24FB3Q55094448-8DF44E70-D80A-44B0-8BB1-9A1554FD2DB2Q55337411-4D47E445-4CC7-4E63-8B94-803B411C9B74Q57138910-56BC7BE5-BBE8-4229-ACD5-34675A1CC468Q57191729-767CD768-3486-4C78-8FEA-7ED2232973F0Q58796913-24C784D6-A381-4D71-A717-DD818C75BD71Q59128091-C69E7084-6889-476F-BF82-A3BAC82A362A
P2860
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
NAD⁺-Metabolizing Ectoenzymes ...... tions: The Human Myeloma Model
@ast
NAD⁺-Metabolizing Ectoenzymes ...... tions: The Human Myeloma Model
@en
NAD⁺-Metabolizing Ectoenzymes ...... tions: The Human Myeloma Model
@nl
type
label
NAD⁺-Metabolizing Ectoenzymes ...... tions: The Human Myeloma Model
@ast
NAD⁺-Metabolizing Ectoenzymes ...... tions: The Human Myeloma Model
@en
NAD⁺-Metabolizing Ectoenzymes ...... tions: The Human Myeloma Model
@nl
prefLabel
NAD⁺-Metabolizing Ectoenzymes ...... tions: The Human Myeloma Model
@ast
NAD⁺-Metabolizing Ectoenzymes ...... tions: The Human Myeloma Model
@en
NAD⁺-Metabolizing Ectoenzymes ...... tions: The Human Myeloma Model
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
NAD⁺-Metabolizing Ectoenzymes ...... tions: The Human Myeloma Model
@en
P2093
A Kate Sasser
Alberto L Horenstein
Andrea Zito
Danilo Marimpietri
Fabio Malavasi
Robert J Oldham
Valeria Quarona
Vito Pistoia
P2860
P304
P3181
P356
10.3390/CELLS4030520
P407
P50
P577
2015-01-01T00:00:00Z